Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma.
Matthias Rastetter, Undraga Schagdarsurengin, Christoph Lahtz, et al.
PubMed (2007) Vol. 22, Iss. 9, pp. 1005-15
Closed Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Clinical implications of intratumor heterogeneity: challenges and opportunities
Santiago Ramón y Cajal, Marta Sesé, Claudia Capdevila, et al.
Journal of Molecular Medicine (2020) Vol. 98, Iss. 2, pp. 161-177
Open Access | Times Cited: 387
Intratumor and Intertumor Heterogeneity in Melanoma
Tomasz M. Grzywa, Wiktor Paskal, Paweł Włodarski
Translational Oncology (2017) Vol. 10, Iss. 6, pp. 956-975
Open Access | Times Cited: 260
Epigenetic heterogeneity in cancer
Mingzhou Guo, Yaojun Peng, Aiai Gao, et al.
Biomarker Research (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 230
Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells
Youssef Al Hmada, Robert T. Brodell, Naji Kharouf, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 470-470
Open Access | Times Cited: 15
Intertumor and Intratumor NY-ESO-1 Expression Heterogeneity Is Associated with Promoter-Specific and Global DNA Methylation Status in Ovarian Cancer
Anna Woloszynska‐Read, Paulette Mhawech‐Fauceglia, Jihnhee Yu, et al.
Clinical Cancer Research (2008) Vol. 14, Iss. 11, pp. 3283-3290
Open Access | Times Cited: 102
Intratumoral Heterogeneity as a Therapy Resistance Mechanism
Rajasekharan Somasundaram, Jessie Villanueva, Meenhard Herlyn
Advances in pharmacology (2012), pp. 335-359
Open Access | Times Cited: 85
DNA methylation/hydroxymethylation in melanoma
Siqi Fu, Haijing Wu, Huiming Zhang, et al.
Oncotarget (2017) Vol. 8, Iss. 44, pp. 78163-78173
Open Access | Times Cited: 63
Variation of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma
Jonathon Parkinson, Helen Wheeler, Adele Clarkson, et al.
Journal of Neuro-Oncology (2007) Vol. 87, Iss. 1, pp. 71-78
Closed Access | Times Cited: 94
Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing
Katherine E. Varley, David G. Mutch, Tina Bocker Edmonston, et al.
Nucleic Acids Research (2009) Vol. 37, Iss. 14, pp. 4603-4612
Open Access | Times Cited: 70
Heterogeneity in Melanoma
Mei Fong Ng, Jacinta L. Simmons, Glen M. Boyle
Cancers (2022) Vol. 14, Iss. 12, pp. 3030-3030
Open Access | Times Cited: 27
Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma
Judit Pallarés, Ana Velasco, Núria Eritja, et al.
Modern Pathology (2008) Vol. 21, Iss. 6, pp. 691-699
Open Access | Times Cited: 72
Frequent occurrence of RASSF1A promoter hypermethylation and merkel cell polyomavirus in merkel cell carcinoma
Peter Helmbold, Christoph Lahtz, Alexander Enk, et al.
Molecular Carcinogenesis (2009) Vol. 48, Iss. 10, pp. 903-909
Open Access | Times Cited: 60
Impact of Natural Compounds on DNA Methylation Levels of the Tumor Suppressor Gene RASSF1A in Cancer
Reinhard Dammann, Antje Richter, Adriana P. Jiménez, et al.
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 10, pp. 2160-2160
Open Access | Times Cited: 44
RASSF10 Promoter Hypermethylation Is Frequent in Malignant Melanoma of the Skin but Uncommon in Nevus Cell Nevi
Peter Helmbold, Antje Richter, Sara K. Walesch, et al.
Journal of Investigative Dermatology (2011) Vol. 132, Iss. 3, pp. 687-694
Open Access | Times Cited: 44
Evaluating DAPK as a therapeutic target
Yide Huang, Ling Chen, Libin Guo, et al.
APOPTOSIS (2013) Vol. 19, Iss. 2, pp. 371-386
Closed Access | Times Cited: 44
RASSF1A suppresses melanoma development by modulating apoptosis and cell‐cycle progression
Mei Yi, Jianbo Yang, Xiang Chen, et al.
Journal of Cellular Physiology (2010) Vol. 226, Iss. 9, pp. 2360-2369
Open Access | Times Cited: 44
High‐frequency p16INK4A promoter methylation is associated with histone methyltransferase SETDB1 expression in sporadic cutaneous melanoma
Maria Kostaki, Argyro D. Manona, Irene Stavraka, et al.
Experimental Dermatology (2014) Vol. 23, Iss. 5, pp. 332-338
Closed Access | Times Cited: 35
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
J.C. Hassel, Antje Sucker, Lutz Edler, et al.
British Journal of Cancer (2010) Vol. 103, Iss. 6, pp. 820-826
Open Access | Times Cited: 43
Heterogeneity and degree of TIMP4, GATA4, SOX18, and EGFL7 gene promoter methylation in non–small cell lung cancer and surrounding tissues
Tatyana Azhikina, Alena Kozlova, Timofey Skvortsov, et al.
Cancer Genetics (2011) Vol. 204, Iss. 9, pp. 492-500
Closed Access | Times Cited: 36
Transcription control of DAPK
Natalya Benderska, Regine Schneider‐Stock
APOPTOSIS (2013) Vol. 19, Iss. 2, pp. 298-305
Closed Access | Times Cited: 33
The apoptosis associated tyrosine kinase gene is frequently hypermethylated in human cancer and is regulated by epigenetic mechanisms
Tanja Haag, Christina E. Herkt, Sara K. Walesch, et al.
Genes & Cancer (2014) Vol. 5, Iss. 9-10, pp. 365-374
Open Access | Times Cited: 31
SUV39H1/DNMT3A‐dependent methylation of the RB1 promoter stimulates PIN1 expression and melanoma development
Garam Kim, Jinyoung Kim, Sung‐Chul Lim, et al.
The FASEB Journal (2018) Vol. 32, Iss. 10, pp. 5647-5660
Closed Access | Times Cited: 28
Molecular Markers of Tumor Progression in Melanoma
Joshua Rother, Dan Jones
Current Genomics (2009) Vol. 10, Iss. 4, pp. 231-239
Open Access | Times Cited: 37
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07
Peter Schraml, Adriana von Teichman, Daniela Mihic‐Probst, et al.
Oncology Reports (2012) Vol. 28, Iss. 2, pp. 654-658
Open Access | Times Cited: 31
Promoter methylation as biomarkers for diagnosis of melanoma: A systematic review and meta‐analysis
Yu Guo, Jianhong Long, Shaorong Lei
Journal of Cellular Physiology (2018) Vol. 234, Iss. 5, pp. 7356-7367
Closed Access | Times Cited: 24
Page 1 - Next Page

Scroll to top